This new disruptive technology must have valuation consequences.
The value of Phylogica, formerly, depended on it's ability to monetise the value of Phylomer patents. The cash sustainability was based on the notion: "you want access to Phylomer proteins - you pay us to do the survey work".
This value proposition remains and is significantly enhanced by the biomarker developments.
The additional new proposition is: "We now have an advanced medical device that is useful for all phases of biomedical screening".
You don't have to be interested in Phylomers because they are drugs ... you can now be interested in Phylomers because they can detect subtle changes in any biochemical process "invented" in living organisms over the last 2.7 billion years (the age of Archaea DNA mined for Phylomers)!!
Others have made the point, this is big news. I think it is worth double underlining this - just so we are all clear!
PYC Price at posting:
1.8¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)